This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Der Gewinn von RAPT Therapeutics wird voraussichtlich um 29% pro Jahr zurückgehen, während der Jahresumsatz um 84.4% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 15.4% pro Jahr sinken.

Wichtige Informationen

-29.0%

Wachstumsrate der Gewinne

-15.44%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.3%
Wachstumsrate der Einnahmen	84.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Mar 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha

Analyseartikel • Jul 16

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Summary RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. If ph1b results are replicated, I expect the ph2 readout to be positive with available patients, despite premature halting of the trial. Subsequently, I expect the lifting of the FDA clinical hold. Read the full article on Seeking Alpha

Analyseartikel • Feb 21

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • May 10

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyseartikel • Oct 12

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Jun 08

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyseartikel • Mar 15

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:RAPT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	N/A	-220	-183	N/A	4
12/31/2027	N/A	-162	-142	N/A	4
12/31/2026	N/A	-91	-99	N/A	4
12/31/2025	N/A	-83	-79	N/A	4
9/30/2025	N/A	-106	-87	-87	N/A
6/30/2025	N/A	-106	-92	-92	N/A
3/31/2025	N/A	-117	-109	-109	N/A
12/31/2024	N/A	-130	-83	-83	N/A
9/30/2024	N/A	-107	-101	-101	N/A
6/30/2024	N/A	-120	-105	-105	N/A
3/31/2024	N/A	-118	-106	-106	N/A
12/31/2023	N/A	-117	-98	-97	N/A
9/30/2023	N/A	-109	-93	-92	N/A
6/30/2023	N/A	-99	-89	-87	N/A
3/31/2023	1	-93	-75	-74	N/A
12/31/2022	2	-84	-72	-71	N/A
9/30/2022	2	-79	-70	-69	N/A
6/30/2022	3	-76	-65	-64	N/A
3/31/2022	3	-73	-63	-63	N/A
12/31/2021	4	-69	-62	-61	N/A
9/30/2021	4	-64	-56	-56	N/A
6/30/2021	5	-60	-54	-53	N/A
3/31/2021	5	-56	-46	-46	N/A
12/31/2020	5	-53	-41	-40	N/A
9/30/2020	4	-53	-31	-31	N/A
6/30/2020	2	-49	-33	-33	N/A
3/31/2020	1	-47	-36	-36	N/A
12/31/2019	N/A	-43	-36	-35	N/A
9/30/2019	N/A	-39	-42	-39	N/A
6/30/2019	N/A	-40	N/A	-36	N/A
3/31/2019	N/A	-37	N/A	-34	N/A
12/31/2018	N/A	-36	N/A	-33	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RAPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RAPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RAPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RAPT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: RAPT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RAPT in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/03/05 23:40
Aktienkurs zum Tagesende	2026/03/02 00:00
Gewinne	2025/09/30
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

RAPT Therapeutics, Inc. wird von 7 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Gao Yi Chen	Berenberg
Guyn Kim	BMO Capital Markets Equity Research
Zegbeh Jallah	Capital One Securities, Inc.

This company has been acquired

RAPT Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 18% to US$18.14

Price target decreased by 21% to US$33.63

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$50.29

Recent updates

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics, Inc. Announces William Ho Leaves as Chief Medical Officer on December 31, 2025

RAPT Therapeutics, Inc. Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

RAPT Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.00002 million.

RAPT Therapeutics, Inc. and Shanghai Jeyou Pharmaceutical Co., Ltd. Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

RAPT Therapeutics, Inc. Announces Board and Committee Appointments

RAPT Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Minimum Closing Bid Price Rule

RAPT Therapeutics, Inc., Annual General Meeting, May 29, 2025

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Wendye R. Robbins Does Not Stand for Election as Director of Rapt Therapeutics, Inc

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

RAPT Therapeutics, Inc. Announces Board Changes

RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Rapt Therapeutics Approves Reduction to Their Workforce

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Price target decreased by 18% to US$18.14

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Price target decreased by 21% to US$33.63

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon (RPT193) in Atopic Dermatitis and its Phase 2a Trial in Asthma

New major risk - Revenue and earnings growth

RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

New major risk - Revenue and earnings growth

New minor risk - Share price stability

RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

New major risk - Revenue and earnings growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.69 loss in 1Q 2022)

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

Insider recently bought US$98k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Insufficient new directors

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$50.29

Price target decreased to US$53.00

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$77k worth of stock

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$69k worth of stock

Chief Scientific Officer exercised options and sold US$65k worth of stock

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.60 loss in 3Q 2020)